Humira for HS: Trial Results, Dosing, and Long-Term Use

Humira (adalimumab) is the first biologic drug approved specifically for hidradenitis suppurativa, and in clinical trials, roughly 42–59% of people with moderate-to-severe HS saw a meaningful clinical response after 12 weeks of weekly injections. That makes it the treatment most dermatologists reach for once antibiotics and other conventional therapies fall short. But “meaningful response” is not the same as remission, the drug does not work for everyone, and sustaining its benefits over years introduces its own set of challenges worth understanding before you start.

What Humira Actually Does in HS Skin

Hidradenitis suppurativa is driven by chronic, runaway inflammation beneath the skin, particularly in areas like the armpits, groin, and under the breasts. The tunnels, nodules, and abscesses that define HS are fueled in part by an overproduction of a signaling molecule called tumor necrosis factor-alpha (TNF-α). Humira is a TNF-α blocker: it binds to that molecule and prevents it from triggering the downstream inflammatory cascade.

Research on HS skin biopsies shows the drug does more than just neutralize one molecule. Adalimumab treatment reduces the production of several inflammatory signals, including IL-1β, and significantly lowers the numbers of immune cells crowding into lesional skin, including dendritic cells, macrophages, and both T cells and B cells.¹ In practical terms, this means the drug is dialing down the entire inflammatory environment in and around HS lesions, not just switching off one pathway.

What the PIONEER Trials Found

The approval of Humira for HS rested primarily on two large phase 3 trials, PIONEER I and PIONEER II. Both enrolled adults with moderate-to-severe disease who had not responded adequately to oral antibiotics. The primary measure was “clinical response” at 12 weeks, defined as at least a 50% reduction in inflammatory lesion count with no increase in abscesses or draining tunnels.

In PIONEER I, about 42% of the weekly adalimumab group achieved that response, compared with 26% on placebo. In PIONEER II, the gap was wider: roughly 59% on adalimumab versus 28% on placebo.² Those numbers are worth sitting with for a moment. Even in the better-performing trial, about four in ten people on the drug did not hit the response bar. And the response bar itself is modest: a 50% drop in lesion count is real improvement, but it is not clearance.

An integrated analysis of the trials also found that the drug performed similarly across disease stages and regardless of whether patients were also on antibiotics.³ That consistency is reassuring: it suggests the drug is not only useful in a narrow subset of patients with a particular disease profile.

How It Affects Pain and Daily Life

For many people with HS, the headline symptom is not the visible lesions but the pain. Deep, throbbing pain in the groin or armpit that makes sitting, walking, or working miserable. This is where Humira often delivers the benefit patients feel most. A meta-analysis of adalimumab trials found a statistically significant reduction in pain scores after 12 weeks compared to placebo.⁴ An earlier randomized trial comparing weekly dosing against placebo found significantly greater improvements in patient-reported pain and overall outcomes with the higher-frequency regimen.⁵

Beyond pain, real-world data from the HARMONY study found that adalimumab improved quality-of-life scores, reduced the impact on work productivity, and cut healthcare visits by about half over the course of a year.⁶ All of those improvements reached statistical significance within the first 12 weeks. For a disease that frequently forces people to miss work, avoid social situations, and cycle through emergency department visits, that kind of improvement matters even when the underlying disease is not cured.

How Long the Benefit Lasts in Practice

Clinical trial data runs for months. Real life runs for years. One of the most important questions about Humira for HS is whether it keeps working over time or whether the benefit fades. A real-world study tracking adalimumab use in HS patients found a median drug survival of about 56 months, meaning half the patients were still on the drug and deriving benefit after nearly five years.⁷ That is longer than many earlier reports suggested.

When patients did stop, the most common reason was that the drug had stopped working well enough, accounting for about half of discontinuations. Adverse effects accounted for roughly a fifth.⁸ So while the drug has real staying power for many, losing effectiveness over time is a recognized and common pattern, not a rare outcome.

When Humira Stops Working and Why

One reason adalimumab can lose effectiveness is immunogenicity: your immune system learns to recognize the drug as foreign and produces anti-drug antibodies (ADAs) that neutralize it. A retrospective study of HS patients with a suboptimal response found that about a quarter had detectable anti-adalimumab antibodies, and every one of those patients had drug levels too low to be effective.⁹ Patients with antibodies had a median adalimumab blood level near zero, while those without antibodies had levels well above the therapeutic threshold.

This is why some dermatologists are increasingly interested in therapeutic drug monitoring: checking blood levels of adalimumab and anti-drug antibodies when a patient’s HS starts flaring again. If the drug level is low because of antibodies, switching to a different biologic usually makes more sense than increasing the dose. If the level is adequate but the disease is still active, the problem is likely that TNF-α blockade alone is not enough for that particular patient’s disease, and a drug targeting a different inflammatory pathway may be needed.

Dose Escalation for Refractory Disease

The standard approved dose for HS in adults is 40 mg injected weekly, after a loading phase. But for patients whose disease responds partially or who lose response, some clinicians try increasing the dose. A retrospective case series found that patients who escalated to 80 mg weekly had a statistically significant increase in blood levels of the drug, and about 44% showed clinical improvement at follow-up, compared with a third of those who stayed at 40 mg weekly.¹⁰

A systematic review of high-dose adalimumab for HS found generally favorable results, with improvements in disease severity and quality of life and no severe adverse events reported, but the authors were careful to note that the evidence base is thin and mostly low-quality.¹¹ Dose escalation is still off-label and is typically reserved for patients who have shown some initial benefit from the standard dose.

Combining Humira with Other Treatments

Humira rarely works in a vacuum. HS management almost always involves some combination of medical and surgical approaches, and the evidence increasingly supports that combinations outperform monotherapy.

One study directly compared starting adalimumab alongside the antibiotics clindamycin and rifampicin versus adalimumab alone. The combination group showed roughly twice the disease improvement, better tunnel reduction, and stronger pain relief.¹² A smaller retrospective chart review noted promising results with other pairings as well, including adalimumab combined with isotretinoin or doxycycline for moderate disease, and adalimumab with cyclosporine for severe, refractory cases.¹³

On the surgical side, the thinking has shifted toward intervening earlier rather than later. Current practice favors pairing medical therapy with early surgical intervention to promote healing and limit scar formation while the disease is still manageable.¹⁴ The SHARPS trial tested adalimumab alongside wide excision surgery for moderate-to-severe HS, and while the combination was safe, outcomes like surgical-site healing and the need for less extensive surgery were similar whether patients were on adalimumab or placebo.¹⁵ This suggests that the benefit of combination may depend on timing and on which surgical procedures are used, rather than being a blanket advantage.

What Screening You Need Before Starting

Because Humira suppresses part of your immune system, certain infections that your body normally keeps in check can reactivate once treatment starts. The most well-established risks are tuberculosis reactivation and hepatitis B reactivation. Consensus guidelines from dermatology groups recommend screening for hepatitis B, hepatitis C, and tuberculosis before starting adalimumab or any other biologic for HS.¹⁶

Screening is not a one-time event. Guidelines suggest repeating hepatitis screening every six months and latent TB screening annually while on adalimumab.¹⁷ If latent TB is found, preventive treatment with anti-TB medications is started before or alongside adalimumab. Additional screening for region-specific infections may also be needed depending on where you live or have traveled.¹⁸

Adolescent Approval and Real-World Results in Teens

In 2018, the FDA expanded the adalimumab label to include adolescents aged 12 and older weighing at least 30 kg. No new clinical trials were run in teens; instead, the approval relied on pharmacokinetic modeling that showed weight-based dosing in adolescents would produce drug levels comparable to those seen in adults.¹⁹ That approach was reasonable given the drug’s long safety track record in pediatric populations with other conditions, but it left clinicians wanting real-world confirmation.

A multicenter case series (ADOLESBIO-HS) provided some of that confirmation. About 77% of adolescents with moderate-to-severe HS achieved clinical response at six months, and the safety profile looked similar to what is seen in adults. Side effects occurred in a minority, and only a few patients required discontinuation, with full recovery.²⁰ The effectiveness numbers were actually better than those seen in adult trials, though smaller sample sizes and a different study design make direct comparison tricky. Still, for adolescents struggling with a disease that hits during an already difficult developmental period, the data is encouraging.

The Biosimilar Question

With the original Humira patent expired, several adalimumab biosimilars are now available, and many patients are being switched for cost reasons. This matters because “biosimilar” means highly similar but not identical, and real-world experience in HS has raised some flags. One multicenter analysis found that patients starting on the originator had longer time to clinical response compared with biosimilars, and those switched from originator to a biosimilar experienced higher rates of losing their response than those kept on the original formulation.²¹

Another study painted a more nuanced picture. It found no statistically significant differences in clinical response between the originator and biosimilar overall, but noted a high discontinuation rate of about 43% among switched patients. The standout finding was that nearly a third of those who stopped the biosimilar did so because of severe pain at the injection site, not because the drug was not working.²² Some biosimilar formulations use a different citrate-based buffer that stings more during injection, and for a drug you inject weekly, that discomfort adds up. In cases where patients could not tolerate the biosimilar, switching back to the originator restored both tolerability and efficacy in roughly two-thirds of cases.²³

If your insurer or pharmacy switches you to a biosimilar, it is not cause for alarm, but it is worth paying attention to whether your disease control or injection-site pain changes. The evidence is still evolving, and the differences between specific biosimilar products may matter more than the originator-versus-biosimilar framing suggests.

Newer Biologics and Where Humira Stands

Adalimumab was alone as an approved biologic for HS for years, but that is changing. Secukinumab (an IL-17A blocker) gained approval for HS more recently, and bimekizumab (which blocks both IL-17A and IL-17F) has been studied in large trials.

A network meta-analysis of phase 3 trials ranked weekly adalimumab as the most effective approved option for reaching a 50% lesion reduction, with statistically significant superiority over secukinumab dosed every two or four weeks.²⁴ Bimekizumab, meanwhile, showed comparable or higher odds of response versus adalimumab in a separate long-term analysis, with notably greater reductions in abscess and tunnel counts.²⁵ These are indirect comparisons, though, not head-to-head trials, so the exact ranking is still debatable.

What this means for you: Humira remains a first-line biologic for HS, but it is no longer the only game in town. If adalimumab has not worked or has stopped working, a switch to a different biologic class targeting IL-17 is now a viable next step rather than an experimental one.

Cardiovascular Inflammation and Broader Health Effects

HS is not just a skin disease. People with moderate-to-severe HS carry a higher burden of systemic inflammation, and that inflammation is increasingly linked to elevated cardiovascular risk. An analysis of the PIONEER trial data found that adalimumab treatment reduced several blood-based markers of systemic inflammation within four weeks, and those reductions held through at least 36 weeks. Patients on placebo showed no such changes.²⁶

A separate study measuring the thickness of carotid artery walls, an early marker of atherosclerosis, found that adalimumab treatment may benefit a subset of HS patients in terms of cardiovascular risk reduction, particularly those who already have traditional cardiovascular risk factors and signs of early plaque buildup.²⁷ This does not mean Humira is a heart drug, but it does suggest that controlling the systemic fire behind HS could have downstream benefits beyond the skin.

Predicting Who Will Respond

One of the frustrations with Humira for HS is that there is no reliable way to know in advance whether you will be among the responders or the non-responders. Researchers have been hunting for blood-based biomarkers that could predict this. One study identified a combination of three markers, calprotectin, fractalkine, and a chemokine called HCC-4, that together reached about 86% accuracy in predicting whether a patient would respond to adalimumab.²⁸ The same study found that non-responders tended to have higher baseline levels of C-reactive protein, a broad inflammation marker, which hints that patients whose inflammation is driven by pathways beyond TNF-α may be less likely to benefit from a TNF-α blocker alone.

These biomarkers are not yet used in routine clinical practice; they remain research tools. But they point toward a future where a blood test before your first injection could help your dermatologist choose between adalimumab and a different biologic from the start, rather than putting you through months of a trial that may not work.

Access and the Cost Problem

Even when Humira is the right treatment, getting and staying on it is not straightforward. A qualitative study of HS patients found that disease flares and employment exist in a vicious cycle: severe flares make it hard to work, losing work means losing insurance, and losing insurance means losing access to expensive biologics.²⁹ Patients also reported that clinician attitudes and knowledge gaps about HS added to the delay in getting appropriate treatment. The cost of originator adalimumab, even with manufacturer copay assistance, and the prior-authorization hurdles imposed by insurers remain significant practical barriers. The arrival of biosimilars has helped bring list prices down, though as discussed earlier, switching comes with its own considerations.

For a disease that disproportionately affects people in their working years and is more prevalent among populations already facing healthcare disparities, these access issues are not peripheral concerns. They shape who actually gets treated with a biologic and who continues to cycle through less effective options.